Related Experiment Video
Updated: May 14, 2026
07:30
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
Published on: July 9, 2016
Recent developments in 5-HT3 receptor pharmacology
1Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QW, UK. ajt44@cam.ac.uk
Trends in Pharmacological Sciences
|February 6, 2013
Summary
New 5-hydroxytryptamine(3) (5-HT(3)) receptor ligands offer insights into receptor function. These compounds, including competitive and non-competitive antagonists, advance understanding and potential applications in medicine.
Area of Science:
- Pharmacology
- Neuroscience
- Molecular Biology
Background:
- The development of 5-hydroxytryptamine(3) (5-HT(3)) receptor antagonists revolutionized antiemetic therapy.
- Receptor cloning and structural biology advances have deepened the understanding of 5-HT(3) receptor physiology and ligand interactions.
Purpose of the Study:
- To review recently identified 5-HT(3) receptor ligands.
- To emphasize the pharmacology and ligand-receptor interactions of these novel compounds.
- To explore their potential in clinical and veterinary research.
Main Methods:
- Literature review of published studies on 5-HT(3) receptor ligands.
- Analysis of pharmacological data, including competitive and non-competitive antagonism.
- Examination of structural information and its relation to ligand binding.
Main Results:
- Over 500 5-HT(3) receptor ligands have been described.
- Ligands include competitive and non-competitive antagonists, with some exhibiting subtype selectivity or allosteric mechanisms.
- Detailed molecular structures aid in reconciling binding-site data.
Conclusions:
- Novel 5-HT(3) receptor ligands provide valuable tools for investigating receptor function.
- Understanding ligand-receptor interactions can lead to new therapeutic strategies.
- These ligands hold promise for future clinical and veterinary applications.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...